Spadin, a sortilin-derived peptide, targeting rodent TREK-1 channels: a new concept in the antidepressant drug design.
Current antidepressant treatments are inadequate for many individuals, and when they are effective, they require several weeks of administration before a therapeutic effect can be observed. Improving the treatment of depression is challenging. Recently, the two-pore domain potassium channel TREK-1 h...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2010
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/1ce8e5d7cde54153ac1956b5d289c1e1 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:1ce8e5d7cde54153ac1956b5d289c1e1 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:1ce8e5d7cde54153ac1956b5d289c1e12021-11-25T05:34:18ZSpadin, a sortilin-derived peptide, targeting rodent TREK-1 channels: a new concept in the antidepressant drug design.1544-91731545-788510.1371/journal.pbio.1000355https://doaj.org/article/1ce8e5d7cde54153ac1956b5d289c1e12010-04-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/20405001/pdf/?tool=EBIhttps://doaj.org/toc/1544-9173https://doaj.org/toc/1545-7885Current antidepressant treatments are inadequate for many individuals, and when they are effective, they require several weeks of administration before a therapeutic effect can be observed. Improving the treatment of depression is challenging. Recently, the two-pore domain potassium channel TREK-1 has been identified as a new target in depression, and its antagonists might become effective antidepressants. In mice, deletion of the TREK-1 gene results in a depression-resistant phenotype that mimics antidepressant treatments. Here, we validate in mice the antidepressant effects of spadin, a secreted peptide derived from the propeptide generated by the maturation of the neurotensin receptor 3 (NTSR3/Sortilin) and acting through TREK-1 inhibition. NTSR3/Sortilin interacted with the TREK-1 channel, as shown by immunoprecipitation of TREK-1 and NTSR3/Sortilin from COS-7 cells and cortical neurons co-expressing both proteins. TREK-1 and NTSR3/Sortilin were colocalized in mouse cortical neurons. Spadin bound specifically to TREK-1 with an affinity of 10 nM. Electrophysiological studies showed that spadin efficiently blocked the TREK-1 activity in COS-7 cells, cultured hippocampal pyramidal neurons, and CA3 hippocampal neurons in brain slices. Spadin also induced in vivo an increase of the 5-HT neuron firing rate in the Dorsal Raphe Nucleus. In five behavioral tests predicting an antidepressant response, spadin-treated mice showed a resistance to depression as found in TREK-1 deficient mice. More importantly, an intravenous 4-d treatment with spadin not only induced a strong antidepressant effect but also enhanced hippocampal phosphorylation of CREB protein and neurogenesis, considered to be key markers of antidepressant action after chronic treatment with selective serotonin reuptake inhibitors. This work also shows the development of a reliable method for dosing the propeptide in serum of mice by using AlphaScreen technology. These findings point out spadin as a putative antidepressant of new generation with a rapid onset of action. Spadin can be regarded as the first natural antidepressant peptide identified. It corresponds to a new concept to address the treatment of depression.Jean MazellaOlivier PétraultGuillaume LucasEmmanuel DevalSophie Béraud-DufourCarine GandinMalika El-YacoubiCatherine WidmannAlice GuyonEric ChevetSaid TaoujiGrégory ConductierAlain CorinusThierry CoppolaGabriella GobbiJean-Louis NahonCatherine HeurteauxMarc BorsottoPublic Library of Science (PLoS)articleBiology (General)QH301-705.5ENPLoS Biology, Vol 8, Iss 4, p e1000355 (2010) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Biology (General) QH301-705.5 |
| spellingShingle |
Biology (General) QH301-705.5 Jean Mazella Olivier Pétrault Guillaume Lucas Emmanuel Deval Sophie Béraud-Dufour Carine Gandin Malika El-Yacoubi Catherine Widmann Alice Guyon Eric Chevet Said Taouji Grégory Conductier Alain Corinus Thierry Coppola Gabriella Gobbi Jean-Louis Nahon Catherine Heurteaux Marc Borsotto Spadin, a sortilin-derived peptide, targeting rodent TREK-1 channels: a new concept in the antidepressant drug design. |
| description |
Current antidepressant treatments are inadequate for many individuals, and when they are effective, they require several weeks of administration before a therapeutic effect can be observed. Improving the treatment of depression is challenging. Recently, the two-pore domain potassium channel TREK-1 has been identified as a new target in depression, and its antagonists might become effective antidepressants. In mice, deletion of the TREK-1 gene results in a depression-resistant phenotype that mimics antidepressant treatments. Here, we validate in mice the antidepressant effects of spadin, a secreted peptide derived from the propeptide generated by the maturation of the neurotensin receptor 3 (NTSR3/Sortilin) and acting through TREK-1 inhibition. NTSR3/Sortilin interacted with the TREK-1 channel, as shown by immunoprecipitation of TREK-1 and NTSR3/Sortilin from COS-7 cells and cortical neurons co-expressing both proteins. TREK-1 and NTSR3/Sortilin were colocalized in mouse cortical neurons. Spadin bound specifically to TREK-1 with an affinity of 10 nM. Electrophysiological studies showed that spadin efficiently blocked the TREK-1 activity in COS-7 cells, cultured hippocampal pyramidal neurons, and CA3 hippocampal neurons in brain slices. Spadin also induced in vivo an increase of the 5-HT neuron firing rate in the Dorsal Raphe Nucleus. In five behavioral tests predicting an antidepressant response, spadin-treated mice showed a resistance to depression as found in TREK-1 deficient mice. More importantly, an intravenous 4-d treatment with spadin not only induced a strong antidepressant effect but also enhanced hippocampal phosphorylation of CREB protein and neurogenesis, considered to be key markers of antidepressant action after chronic treatment with selective serotonin reuptake inhibitors. This work also shows the development of a reliable method for dosing the propeptide in serum of mice by using AlphaScreen technology. These findings point out spadin as a putative antidepressant of new generation with a rapid onset of action. Spadin can be regarded as the first natural antidepressant peptide identified. It corresponds to a new concept to address the treatment of depression. |
| format |
article |
| author |
Jean Mazella Olivier Pétrault Guillaume Lucas Emmanuel Deval Sophie Béraud-Dufour Carine Gandin Malika El-Yacoubi Catherine Widmann Alice Guyon Eric Chevet Said Taouji Grégory Conductier Alain Corinus Thierry Coppola Gabriella Gobbi Jean-Louis Nahon Catherine Heurteaux Marc Borsotto |
| author_facet |
Jean Mazella Olivier Pétrault Guillaume Lucas Emmanuel Deval Sophie Béraud-Dufour Carine Gandin Malika El-Yacoubi Catherine Widmann Alice Guyon Eric Chevet Said Taouji Grégory Conductier Alain Corinus Thierry Coppola Gabriella Gobbi Jean-Louis Nahon Catherine Heurteaux Marc Borsotto |
| author_sort |
Jean Mazella |
| title |
Spadin, a sortilin-derived peptide, targeting rodent TREK-1 channels: a new concept in the antidepressant drug design. |
| title_short |
Spadin, a sortilin-derived peptide, targeting rodent TREK-1 channels: a new concept in the antidepressant drug design. |
| title_full |
Spadin, a sortilin-derived peptide, targeting rodent TREK-1 channels: a new concept in the antidepressant drug design. |
| title_fullStr |
Spadin, a sortilin-derived peptide, targeting rodent TREK-1 channels: a new concept in the antidepressant drug design. |
| title_full_unstemmed |
Spadin, a sortilin-derived peptide, targeting rodent TREK-1 channels: a new concept in the antidepressant drug design. |
| title_sort |
spadin, a sortilin-derived peptide, targeting rodent trek-1 channels: a new concept in the antidepressant drug design. |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2010 |
| url |
https://doaj.org/article/1ce8e5d7cde54153ac1956b5d289c1e1 |
| work_keys_str_mv |
AT jeanmazella spadinasortilinderivedpeptidetargetingrodenttrek1channelsanewconceptintheantidepressantdrugdesign AT olivierpetrault spadinasortilinderivedpeptidetargetingrodenttrek1channelsanewconceptintheantidepressantdrugdesign AT guillaumelucas spadinasortilinderivedpeptidetargetingrodenttrek1channelsanewconceptintheantidepressantdrugdesign AT emmanueldeval spadinasortilinderivedpeptidetargetingrodenttrek1channelsanewconceptintheantidepressantdrugdesign AT sophieberauddufour spadinasortilinderivedpeptidetargetingrodenttrek1channelsanewconceptintheantidepressantdrugdesign AT carinegandin spadinasortilinderivedpeptidetargetingrodenttrek1channelsanewconceptintheantidepressantdrugdesign AT malikaelyacoubi spadinasortilinderivedpeptidetargetingrodenttrek1channelsanewconceptintheantidepressantdrugdesign AT catherinewidmann spadinasortilinderivedpeptidetargetingrodenttrek1channelsanewconceptintheantidepressantdrugdesign AT aliceguyon spadinasortilinderivedpeptidetargetingrodenttrek1channelsanewconceptintheantidepressantdrugdesign AT ericchevet spadinasortilinderivedpeptidetargetingrodenttrek1channelsanewconceptintheantidepressantdrugdesign AT saidtaouji spadinasortilinderivedpeptidetargetingrodenttrek1channelsanewconceptintheantidepressantdrugdesign AT gregoryconductier spadinasortilinderivedpeptidetargetingrodenttrek1channelsanewconceptintheantidepressantdrugdesign AT alaincorinus spadinasortilinderivedpeptidetargetingrodenttrek1channelsanewconceptintheantidepressantdrugdesign AT thierrycoppola spadinasortilinderivedpeptidetargetingrodenttrek1channelsanewconceptintheantidepressantdrugdesign AT gabriellagobbi spadinasortilinderivedpeptidetargetingrodenttrek1channelsanewconceptintheantidepressantdrugdesign AT jeanlouisnahon spadinasortilinderivedpeptidetargetingrodenttrek1channelsanewconceptintheantidepressantdrugdesign AT catherineheurteaux spadinasortilinderivedpeptidetargetingrodenttrek1channelsanewconceptintheantidepressantdrugdesign AT marcborsotto spadinasortilinderivedpeptidetargetingrodenttrek1channelsanewconceptintheantidepressantdrugdesign |
| _version_ |
1718414562884059136 |